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Abstract 22 
Dihydroartemisinin-piperaquine (DP) offers prolonged protection against malaria, but its 23 
impact on Plasmodium falciparum drug sensitivity is uncertain. In a trial of intermittent 24 
preventive treatment in schoolchildren in Tororo, Uganda in 2011-12, monthly DP for one 25 
year decreased the incidence of malaria by 96% compared to placebo; DP once per school 26 
term offered protection primarily during the first month after therapy. To assess the impact 27 
of DP on selection of drug resistance, we compared the prevalence of key polymorphisms in 28 
isolates that emerged at different intervals after treatment with DP. Blood obtained 29 
monthly and at each episode of fever was assessed for P. falciparum parasitemia by 30 
microscopy. Samples from 160 symptomatic and 650 asymptomatic episodes of parasitemia 31 
were assessed at 4 loci (N86Y, Y184F, and D1246Y in pfmdr1 and K76T in pfcrt) that 32 
modulate sensitivity to aminoquinoline antimalarials utilizing a ligase detection reaction 33 
fluorescent microsphere assay. For pfmdr1 N86Y and pfcrt K76T, but not the other studied 34 
polymorphisms, the prevalences of mutant genotypes were significantly greater in children 35 
who had received DP within the past 30 days compared to those not treated within 60 days 36 
(86Y 18.0% vs. 8.3%, p=0.03; 76T 96.0% vs. 86.1%, p=0.05), suggesting selective pressure of 37 
DP. Full sequencing of pfcrt in a subset of samples did not identify additional polymorphisms 38 
selected by DP. In summary, parasites that emerged soon after treatment with DP were 39 
more likely than parasites not under drug pressure to harbor pfmdr1 and pfcrt 40 
polymorphisms associated with decreased sensitivity to aminoquinoline antimalarials.  41 
  42 
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Introduction 43 
Malaria, in particular infection with Plasmodium falciparum, remains a huge public 44 
health problem, with the highest disease burden in sub-Saharan Africa (1, 2). Important 45 
advances have been made in malaria control recently, with a significant decrease in malaria 46 
burden and progress towards elimination noted in some areas (3). Among key tools in the 47 
control of malaria is intermittent preventive treatment (IPT), the provision of full treatment 48 
courses at regular intervals to high risk populations (4). IPT is standard practice during 49 
pregnancy (IPTp), is recommended in children living in seasonal malaria transmission 50 
settings as seasonal malaria chemoprevention (5), and is being investigated in other 51 
populations (6-9).  However, currently IPT is advocated only with sulfadoxine-52 
pyrimethamine (SP) or a combination of SP and amodiaquine (SP+AQ) (5, 10), regimens 53 
severely compromised by drug resistance in much of Africa (11-13). For malaria treatment, 54 
older regimens have been replaced by artemisinin-based combination therapies (ACTs), and 55 
a similar change may be warranted for IPT.  56 
Dihydroartemisinin-piperaquine (DP), which provides rapid killing of most parasites 57 
by dihydroartemisinin, prolonged action against any remaining parasites by piperaquine, 58 
and protection for weeks after therapy due to the long half-life of piperaquine, has recently 59 
been investigated for IPT. Compared to IPTp with SP, IPTp with DP was associated with 60 
lower risks of P. falciparum infection and symptomatic malaria during pregnancy in Kenya 61 
(14) and Uganda (15). In Ugandan schoolchildren, monthly IPT with DP was associated with 62 
reduced incidence of malaria and reduced prevalence of parasitemia and anemia compared 63 
to DP given approximately once every three months or placebo (6, 16). Similar results were 64 
observed in Ugandan infants when monthly IPT with DP was compared with daily 65 
trimethoprim-sulfamethoxazole or monthly SP (7). Thus, DP is a promising alternative to SP 66 
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or SP+AQ for IPT, but its benefits may be undone by the emergence of P. falciparum 67 
resistance to either component of the combination.   68 
Mediators of decreased drug sensitivity and selective pressures for resistance are 69 
quite well understood for some antimalarial drugs. Resistance to the aminoquinolines 70 
chloroquine and amodiaquine is mediated largely by polymorphisms in putative drug 71 
transporters encoded by pfcrt and pfmdr1 (13, 17), and these polymorphisms are selected in 72 
new infections that emerge soon after therapy with artesunate-AQ (AS/AQ) (18, 19). 73 
Piperaquine is a bisaminoquinoline related to chloroquine and amodiaquine. Resistance to 74 
piperaquine was widely reported during the pre-artemisinin era in China (20), and recently 75 
clinically relevant resistance, with frequent recrudescences after therapy with DP, has been 76 
noted in Cambodia(21-23). However, mechanisms of resistance to piperaquine are 77 
uncertain. Use of DP for treatment (24) or chemoprevention (25) did not select for the 78 
polymorphisms associated with chloroquine resistance in Burkina Faso, but in Uganda 79 
recent treatment with DP selected for pfmdr1 mutations associated with decreased 80 
sensitivity to aminoquinolines (26). Interestingly, some other antimalarials, notably 81 
lumefantrine, which is a component of the Ugandan first-line antimalarial regimen 82 
artemether-lumefantrine (AL), exert the opposite selective pressure. Thus, new infections 83 
emerging within two months of treatment with AL showed selection of wild-type sequences 84 
at the pfcrt K76T and pfmdr1 N86Y and D1246Y alleles (26-29); mutant sequences are 85 
selected at these same alleles by aminoquinolines. Of recent concern has been resistance to 86 
artemisinins, manifest as delayed parasite clearance after therapy, in Southeast Asia (22, 30-87 
32), but recent studies utilizing clinical, parasitological, and molecular markers (33, 34) 88 
suggest that the artemisinin-resistant phenotype is not yet prevalent in Uganda (26, 35, 36) 89 
or other parts of Africa (37, 38).  90 
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Taken together, available evidence suggests that DP may select for the same P. 91 
falciparum polymorphisms as other aminoquinolines, leading to decreased treatment or 92 
preventive efficacy of DP, but data on the effects of IPT with DP are very limited. We 93 
therefore assessed the prevalences of key polymorphisms in isolates that emerged at 94 
different intervals after treatment with DP using samples from a recent trial evaluating IPT 95 
with DP in Ugandan schoolchildren. 96 
 97 
Methods 98 
Clinical trial. Study samples were from a randomized, double-blinded, placebo-99 
controlled trial conducted in Tororo, Uganda from 2011 to 2012 (6, 39). In brief, 740 100 
schoolchildren aged 6–14 years from one primary school in Mulanda sub-county, Tororo 101 
District were enrolled and randomized 1:1:1 to one of three study arms: DP monthly, DP 102 
once per school term (four treatments over 12 months), or placebo. DP was administered 103 
according to weight based guidelines and treatment was directly observed. Finger-prick 104 
blood samples were obtained at enrollment, every month, and with every episode of fever 105 
to assess for malaria infection by thick blood smear, and for storage on filter paper. 106 
Episodes of uncomplicated malaria were treated with AL. Children were followed for 12 107 
months. The trial was approved by the Uganda National Council for Science and Technology 108 
and the Makerere University School of Medicine Research and Ethics Committee and 109 
registered at ClinicalTrials.gov (NCT01231880). Molecular studies were also approved by the 110 
University of California, San Francisco Committee on Human Research. 111 
Selection of samples for testing of parasite polymorphisms. We considered all 112 
samples that were positive for P. falciparum parasitemia based on evaluation of Giemsa-113 
stained thick blood smears, as previously described (6).  A total of 160 symptomatic and 114 
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1,522 asymptomatic episodes of P. falciparum parasitemia were documented. The number 115 
of samples analysed was determined by estimating the power for two-sample comparison 116 
of proportions using effect sizes observed for each mutant polymorphism in a recent study 117 
in Tororo (0.34 for pfmdr1 N86Y, 0.11 for pfmdr1 D1246Y, 0.04 for pfmdr1 184F, and 0.09 118 
for pfcrt K76), fixing α at 0.05 (26). The sample size giving the maximum power was 119 
considered in the analysis.  From these estimates, we analysed all 160 samples from 120 
symptomatic episodes, all 50 samples from children with recurrent parasitemia within 13-30 121 
days of prior therapy with DP, and 600 samples randomly selected from children with either 122 
recurrent parasitemia >30 days after prior therapy with DP or from the control arm of the 123 
study. All samples were analyzed for 4 common P. falciparum polymorphisms known to be 124 
associated with drug sensitivity: pfcrt K76T, and pfmdr1 N86Y, Y184F, and D1246Y. A subset 125 
of 25 samples from children with prior DP therapy within 13-30 days and 25 randomly 126 
selected paired samples from children in the control arm (each pair matched for collection 127 
within 15 days of each other) were subjected to sequencing of the complete pfcrt gene. 128 
Characterization of 4 pfcrt and pfmdr1 polymorphisms. DNA was extracted from 129 
filter paper blood spots into 100 μL of water using Chelex-100 as previously described (40). 130 
Gene fragments spanning all loci of interest were amplified in nested reactions (26), and 131 
failed reactions were repeated. To detect polymorphisms, multiplex ligase detection 132 
reaction–fluorescent microsphere assays were performed as previously described (26, 41).  133 
Sequencing of pfcrt. For a subset of samples pfcrt was sequenced from DNA samples 134 
as previously described (42) with minor modifications.  Briefly, pfcrt was amplified in 3 135 
nested-PCR reactions, covering exons 1-2, 3-8, and 9-13, using the published primer 136 
sequences.  For both rounds of PCR, each 25 µL reaction contained 2 mM MgSO4, 200 µM 137 
each dNTP, 1 µM each primer, 1X PCR Buffer, and 2U Platinum Taq DNA Polymerase High 138 
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Fidelity (Invitrogen). Conditions for all reactions were 94oC for 2 min; 30 cycles of 94oC for 139 
20 sec, 47oC for 10 sec, and 60oC for 3 min; and a final extension at 60oC for 5 min.  140 
Amplicons were cloned with the TOPO-TA Cloning Kit for Sequencing and transfected into 141 
One Shot TOP10 chemically competent E. coli (Invitrogen) according to the manufacturer’s 142 
instructions. Colonies were grown overnight under kanamycin selection, picked, and 143 
incubated in LB broth with kanamycin.  Plasmid DNA was purified using the PureLink Quick 144 
Plasmid Miniprep Kit (Invitrogen), digested with EcoRI to confirm the insert size, and then 145 
sequenced (Eurofins) using M13 forward and reverse primers.  DNA sequence data were 146 
assembled and edited, and mutations were detected by alignment and comparison it to the 147 
expected sequence using CodonCode Aligner v. 5.1.5.  Multiple clones were sequenced to 148 
distinguish true polymorphisms from PCR errors, including at least 3 clones for all but 3 149 
fragments, for which 2 clones were sequenced.  150 
Statistical analysis. Data analysis was done using Stata version 14 (StataCorp). 151 
Outcomes of interest were the prevalence of pure mutant alleles for each locus of interest. 152 
The exposure variable of interest was duration since prior DP dose, evaluated as a 153 
categorical variable split into 13 – 30, 31 – 60, and > 60 days (including the no treatment 154 
control group) since the last treatment. Associations between outcomes and duration since 155 
last treatment and differences between prevalences of pfcrt alleles were measured using 156 
Fisher’s exact test and expressed as relative risk. In all analyses, a 2-tailed P value <0.05 was 157 
considered statistically significant.  158 
 159 
Results  160 
Study samples. A total of 740 schoolchildren aged 6 – 14 years were randomized to 161 
one of the 3 study arms in the parent study and followed for one year from 2011 to 2012. As 162 
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previously reported, compared to either DP once per school term (approximately every 3 163 
months) or placebo, monthly DP offered strong protective efficacy against malaria (6). For 164 
this sub-study, samples collected from children with blood smears positive for P. falciparum 165 
were analyzed (Table 1). As expected due to the protective efficacy of monthly DP, fewer 166 
samples were available from this study arm than from children who received placebo or DP 167 
once per school term. A total of 810 samples from 160 symptomatic and 650 asymptomatic 168 
episodes of parasitemia were assessed (Table 1). Samples were analysed for common 169 
polymorphisms in pfmdr1 and pfcrt. Genotyping results were available for pfcrt K76T in 806 170 
(99.5%) samples and for pfmdr1 N86Y, N184Y, and D1246Y in 800 (98.8%), 810 (100%), and 171 
784 (96.8%) samples, respectively, and these results were included in the analysis. 172 
Prevalence of pfcrt and pfmdr1 polymorphisms. The prevalence of the 4 studied 173 
polymorphisms was similar to that in contemporaneous samples from Tororo that were 174 
reported previously (43). For two polymorphisms, pfcrt K76T and pfmdr1 N86Y, the 175 
prevalence of mutant genotypes was significantly higher in samples from children who had 176 
received DP within 30 days compared to those from children who had not received DP 177 
within 60 days (Table 2). For the other studied polymorphisms the prevalence of genotypes 178 
did not differ between children who had or had not received recent therapy with DP. 179 
Matching for duration since a prior episode, there was no difference in the prevalence of 180 
pfcrt and pfmdr1 mutant alleles between samples from children with symptomatic or 181 
asymptomatic parasitemia (data not shown).   182 
Sequencing of pfcrt. As DP may select for additional polymorphisms in pfcrt, we 183 
sequenced the gene in a subset of 25 parasitemic samples under strong selective pressure 184 
as indicated by emergence within 30 days of prior therapy with DP and in 25 paired samples 185 
collected near the same date from children who did not receive DP.  We successfully 186 
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sequenced the full gene in 17 pairs.  We identified 9 polymorphisms, 6 of which are 187 
commonly reported in African isolates (Supplemental Table 1). All isolates had the pfcrt 72-188 
76 CVIET or a mix of the CVIET and CVMNT haplotype, except for one isolate that had the 189 
pfcrt 72S mutation, resulting in the SVIET haplotype (in all 6 clones from a patient not 190 
receiving DP). Two additional polymorphisms, L50P and F112I, were each identified in at 191 
least 2 clones from a single isolate, the 50P mutation in a control isolate and the 112I 192 
mutation in an isolate from a child recently treated with DP (Supplemental Table 2).  We 193 
found 9 pfcrt haplotypes; the majority (76% in the DP arm and 65% in the control arm) were 194 
mutant at the six loci that are commonly mutant in Africa (74I, 75E, 76T, 220S, 271E, 371I) 195 
(17). Overall, we saw no evidence that DP selected for novel pfcrt polymorphisms in 196 
Ugandan children.  197 
 198 
Discussion 199 
Monthly IPT with DP was highly efficacious in reducing the risks of symptomatic 200 
malaria, parasitemia, and anemia in Ugandan schoolchildren (6). However, the  201 
chemoprophylactic benefits of a long-acting antimalarial such as piperaquine  may be 202 
accompanied by selection of drug resistant parasites (13). We tested whether DP selected 203 
for parasites with genotypes associated with altered sensitivity to aminoquinolines. 204 
Compared to parasites not under drug pressure, those that emerged within 30 days of IPT 205 
with DP were more likely to harbor two mutations, pfmdr1 86Y and pfcrt 76T; these 206 
mutations are associated with resistance to chloroquine and amodiaquine (36, 43-45).  207 
Thus, the marked preventive efficacy of IPT with DP may be accompanied by selection of 208 
decreased sensitivity to aminoquinolines.   209 
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Resistance to chloroquine and amodiaquine is mediated primarily by polymorphisms 210 
in putative drug transporters encoded by pfcrt and pfmdr1 (13, 46). The pfcrt 76T and 211 
pfmdr1 86Y and 1246Y mutations are selected in new infections that emerge soon after 212 
therapy with regimens including chloroquine or amodiaquine (47). Piperaquine is a related 213 
bisaminoquinoline, but mechanisms of resistance are uncertain, and studies of the selective 214 
pressure exerted by DP have yielded conflicting results. Specifically, use of DP for treatment 215 
(48), or chemoprevention (25), did not select for the polymorphisms associated with 216 
aminoquinoline resistance in Burkina Faso, but, in Uganda, recent treatment with DP 217 
selected for the  pfmdr1 86Y and 1246Y mutations (26). Our new results shed additional 218 
light on this area. In the setting of IPT in schoolchildren, recent receipt of DP was associated 219 
with selection of the pfmdr1 86Y and pfcrt 76T mutations, but not the pfmdr1 1246Y 220 
mutation. Differing results may have been due to the changing baseline of polymorphism 221 
prevalence in Uganda, with decreasing prevalence of pfmdr1 1246Y and pfcrt 76T over time. 222 
Differences in results between West and East Africa may also be explained by differences in 223 
parasite backgrounds; of note, the pfmdr1 1246Y mutation, which until recently was 224 
widespread in Uganda, has consistently been uncommon in Burkina Faso (24, 25, 28).  225 
Importantly, although we lack a head-to-head comparison, it appears that DP does 226 
not select as readily as other ACTs for key transporter mutations. In multiple studies the 227 
selective pressure of AS/AQ was marked (49), including a recent trial that showed the 228 
prevalence of the pure pfmdr1 86Y mutation to rise from 59% at baseline to 99% in 229 
recurrent infections within one month of treatment (50). AL also exerts strong selective 230 
pressure, but in the opposite direction, with selection of wild type pfcrt K76 and pfmdr1 N86 231 
and N1246 sequences in parasites that emerge soon after therapy (19, 29). Our recent 232 
findings indicate that DP selects for resistance in a manner similar to that of the other 233 
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aminoquinolines, but associations between recent therapy and transporter polymorphisms 234 
were less marked, suggesting that the selective pressure of DP is lower than that of other 235 
regimens. This difference might be due to different mechanisms of transport for 236 
piperaquine, a much larger molecule compared to chloroquine or amodiaquine. 237 
We were concerned that IPT with DP might select for additional resistance-mediating 238 
P. falciparum polymorphisms. Polymorphisms in addition to those commonly described in 239 
African isolates have been identified in other regions, in some cases with biochemical and 240 
clinical consequences (51, 52). Sequencing of pfcrt in a subset of samples either under or 241 
not under the selective pressure of DP identified a few previously unidentified pfcrt 242 
mutations, but it did not suggest that additional polymorphisms were selected by DP.  243 
Our results have important implications for the use of DP for IPT. Although it offers 244 
great promise for decreasing the malaria burden, DP use may be accompanied by selection 245 
of parasites with decreased sensitivity to DP, and also to the related ACT AS/AQ. 246 
Consideration of the opposite resistance pressures of different antimalarials has led some to 247 
recommend multiple or rotating first-line antimalarial regimens (53). For example, AS/AQ 248 
and AL have opposite selective pressures on pfcrt and pfmdr1 such that each regimen 249 
should blunt selection of resistance to the other. Our results are consistent with a prior 250 
study in Uganda indicating that DP has similar selective pressure to that of AS/AQ. Thus, 251 
considering resistance selection, using DP in IPT might be best advised when the standard 252 
treatment regimen is AL, such that the treatment and IPT regimens offer mutual protection 253 
against selection of resistance. Further, our results suggest that, with changing treatment 254 
and control practices, continued surveillance for clinical, biochemical, and molecular 255 
markers of antimalarial drug resistance in Africa is an important priority.  256 
 257 
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Table 1. Characteristics of study children that supplied samples and of episodes selected 
for analysis 
Characteristics of children with at least one episode 
of parasitemia 
N=389 
Median age (IQR) 9 (7 – 11) 
Median duration of observation in days (IQR) 366 (365 – 368)  
Female sex (n, %) 209 (53.7) 
Study group n (%)  
Placebo 178 (45.8) 
IPT once a school term 178 (45.8) 
Monthly IPT 33 (8.4) 
Characteristics of episodes of parasitemia N=810 
Malaria classification n (%)  
Asymptomatic episodes  650 (80.2) 
Clinical episodes 160 (19.8) 
Study group n (%)  
Placebo 334 (41.3) 
IPT once a school term 419 (51.7) 
Monthly IPT 57 (7.0) 
Duration since prior treatment n (%)  
15 – 30 days 50 (6.2) 
31 – 60 days 122 (15.1) 
61 – 90 days 170 (20.9) 
>90 days 134 (16.5) 
No treatment 334 (41.2) 
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Table 2: Prevalence of P. falciparum pure mutant alleles stratified by time since last dose of DP. 
Allele Days since last 
dose of DP 
Prevalence of wild-type, mixed, and mutant alleles 
n/N (%) 
RR for mutant genotype 
(95% CI) 
p-value 
  Wild type Mixed Mutant   
pfmdr1 
N86Y 
>60a 189/630 (30.0) 389/630 (62.7) 52/630 (8.3) 1  
31 – 60 53/120 (44.2) 57/120 (47.5) 10/120 (8.3) 1.01 (0.53 – 1.93) 0.98 
13 – 30 25/50 (50.0) 32/50 (32.0) 9/50 (18.0) 2.18 (1.14 – 4.16) 0.03 
pfmdr1 
N184Y 
>60a 143/638 (22.4) 458/638 (68.8) 37/638 (5.8) 1  
31 – 60 25/122 (20.5) 84/122 (68.8) 13/122 (10.7) 1.84 (1.01 – 3.35) 0.07 
13 – 30 21/50 (42.0) 28/50 (56.0) 1/50 (2.0) 0.34 (0.05 – 2.46) 0.51 
pfmdr1 
D1246Y 
>60a 261/616 (42.4) 292/616 (47.4) 63/616 (10.2) 1  
31 – 60 59/120 (49.2) 51/120 (42.5) 10/120 (8.3) 0.81 (0.43 – 1.54) 0.62 
13 – 30 24/48 (50.0) 21/48 (43.7) 3/48 (6.3) 0.61 (0.20 – 1.87)  0.61 
pfcrt 
K76T 
>60a 9/635 (1.4) 79/635 (12.4) 547/635 (86.1) 1  
31 – 60 1/121 (0.8) 13/121 (10.7) 107/121 (88.4) 1.03 (0.96 – 1.10) 0.56 
13 – 30 1/50 (2.0) 1/50 (2.0) 48/50 (96.0) 1.11 (1.04 – 1.19) 0.05 
aIncludes those given no drug (placebo group) 
Supplemental Table 1. Non-synonymous polymorphisms detected by sequencing of pfcrt in 
Ugandan isolates. 
pfcrt Allele Treatment 
Arma 
Wild 
type 
N (%) 
Mixed 
N (%) 
Mutant 
N (%) 
P-valueb 
L50P 
DP 17 (100) 0 (0) 0 (0) 
 p = 1.000 
Control 16 (94) 1 (6) 0 (0) 
C72S 
DP 17 (100) 0 (0) 0 (0) 
 p = 1.000 
Control 16 (94) 0 (0) 1 (6) 
M74I 
DP 0 (0) 2 (12) 15 (88) 
p = 0.6552 
Control 0 (0) 4 (24) 13 (76) 
N75E 
DP 0 (0) 2 (12) 15 (88) 
p = 0.6552 
Control 0 (0) 4 (24) 13 (76) 
K76T 
DP 0 (0) 2 (12) 15 (88) 
p = 0.6552 
Control 0 (0) 4 (24) 13 (76) 
F112I 
DP 16 (94) 1 (6) 0 (0) 
 p = 1.000 
Control 17 (100) 0 (0) 0 (0) 
A220S 
DP 0 (0) 2 (12) 15 (88) 
 p = 1.000 
Control 1 (6) 0 (0) 16 (94) 
Q271E 
DP 0 (0) 2 (12) 15 (88) 
 p = 1.000 
Control 1 (6) 0 (0) 16 (94) 
R371I 
DP 1 (6) 0 (0) 16 (94) 
p = 0.60 
Control 3 (18) 0 (0) 14 (82) 
aSamples from the DP arm were parasites emerging 15-30 days after therapy with DP; controls were from the placebo 
group that did not receive DP.  
bP-values are based on comparison of prevalence between treatment arms using Fisher’s exact test. 
  
Supplemental Table 2. Pfcrt haplotypes seen in sequenced samples.   
Haplotype 
Treatment arm 
L50P C72S M74I N75E K76T F112I A220S Q271E R371I DP  
N (%) 
Control 
N (%) 
1 13 (76) 11 (65) L C I E T F S E I 
2 1 (6) 2 (12) L C M/I N/E K/T F S E R 
3 0 (0) 1 (6) L C M/I N/E K/T F S E I 
4 0 (0) 1 (6) L S I E T F S E I 
5 0 (0) 1 (6) L C I E T F A Q R 
6 1 (6) 0 (0) L C I E T F A/S Q/E I 
7 1 (6) 0 (0) L C M/I N/E K/T F A/S Q/E I 
8 1 (6) 0 (0) L C I E T F/I S E I 
9 0 (0) 1 (6) L/P C I E T F S E I 
Loci with two alleles indicate a mixed genotype. 
 
 
